Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069630 | 0.86 | PTGS2 (0.66) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL678225 | 0.86 | PTGS2 (0.84) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL15257349 | 0.84 | PTGS2 (0.60) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL6069777 | 0.83 | PTGS2 (0.63) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL6069533 | 0.83 | MAP4K4 (0.64) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL6069906 | 0.83 | PTGS2 (0.63) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5210195 | 0.82 | PTGS2 (0.82) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL30988052 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL14163961 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL4680 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140194-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINED TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | claimed |
| US-9085532-B2 | Process for preparing a ketosulfone derivative | ZACH SYSTEM S.P.A. (IT) | 2015-07-21 | — | — | US | disclosed |
| US-20150133671-A1 | The Process For Preparing a Ketosulfone Derivative | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2015-05-14 | — | — | US | disclosed |
| EP-1303308-A2 | ALDOSTERONE ANTAGONIST AND CYCLOOXYGENASE-2 INHIBITOR COMBINATION THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED CARDIOVASCULAR DISORDERS | Pharmacia Corporation (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002009759-A2 | ALDOSTERONE ANTAGONIST AND CYCLOOXYGENASE-2 INHIBITOR COMBINATION THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133671-A1 | The Process For Preparing a Ketosulfone Derivative | PDK3, PDK4, PDK2 | PTGS2 2134/4885PTGS1 2064/4885ABCC4 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.